Adalvo acquires its first branded product, Onsolis®
Adalvo announce the acquisition of Adalvo's first branded product, Onsolis® after concluding a deal with a reputable US based specialty pharmaceutical Company, who originally owned the product.
The brand is an opioid analgesic, indicated in the management of persistent breakthrough pain, in cancer patients who have already received and are tolerant to opioid therapy for their underlying cancer pain. Adalvo will be the sole and exclusive owner of the brand and will obtain full rights on the product, taking over all existing business and all market authorizations, globally, including the US.
The brand is being sold in several EU countries and in Taiwan by business partners. Adalvo will assume the supply responsibility and business continuity for these partners.
Anil Okay, CEO at Adalvo
This acquisition paves the way towards a transformative journey, at Adalvo. It is a real game changer, and we are thrilled to be venturing into the branded product domain, growing our position as a global partner of choice.
Adalvo's business remains fuelled by Adalvo's passion for relentless commitment to the partner network that Adalvo serve, and will continue to bring high value assets to Adalvo's portfolio, now venturing also within the branded product domain.
Fur further information visit Adalco.com